
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$74.77
+$1.69 · +2.31%
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Previous close
$74.77
+$1.69 · +2.31%
After-hours
$74.77
$0.00 · 0.00%
Oct 9, 7:55 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
96
Deep Value
Sentiment
66
Bullish
Risk
43
Elevated Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Day range
Current $74.77
52-week range
Current $74.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.47B USD | 9.26B USD | 8.54B USD | 8.08B USD | 7.78B USD |
| Cost of goods sold | 2.79B USD | 2.86B USD | 2.71B USD | 2.6B USD | 2.46B USD |
| Gross profit | 6.67B USD | 6.4B USD | 5.83B USD | 5.48B USD | 5.31B USD |
| Research and development | 698M USD | 686M USD | 614M USD | 539M USD | 508M USD |
| Selling, general, and administrative | 2.38B USD | 2.32B USD | 2.15B USD | 2.01B USD | 2B USD |
| Operating expenses | 3.08B USD | 3B USD | 2.77B USD | 2.55B USD | 2.51B USD |
| Interest income | 93M USD | 106M USD | 105M USD | 50M USD | 6M USD |
| Interest expense | 243M USD | 242M USD | 258M USD | 237M USD | 236M USD |
| Depreciation and amortization | 487M USD | 497M USD | 491M USD | 465M USD | 448M USD |
| Operating income | 3.6B USD | 3.39B USD | 3.07B USD | 2.93B USD | 2.8B USD |
| Net income | 2.67B USD | 2.49B USD | 2.34B USD | 2.11B USD | 2.04B USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$87.33
16.80% upsideCash distributions grouped by calendar year; partial years are marked.
$2.00
2025 complete year+100.0% since 2021
2026 partial: $1.59
$1.00
2,021
$1.30
2,022
$1.50
2,023
$1.728
2,024
$2.00
2,025
$1.59
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Oct 30, 2026 | $0.53Quarterly | Oct 30, 2026 | Dec 1, 2026 |
Dividend | Jul 20, 2026 | $0.53Quarterly | Jul 20, 2026 | Sep 1, 2026 |
Dividend | Apr 20, 2026 | $0.53Quarterly | Apr 20, 2026 | Jun 2, 2026 |
Dividend | Jan 20, 2026 | $0.53Quarterly | Jan 20, 2026 | Mar 3, 2026 |
Dividend | Oct 31, 2025 | $0.50Quarterly | Oct 31, 2025 | Dec 2, 2025 |
Dividend | Jul 18, 2025 | $0.50Quarterly | Jul 18, 2025 | Sep 3, 2025 |
Ex-dividend Oct 30, 2026
$0.53
Quarterly
Record Oct 30, 2026 · Payment Dec 1, 2026
Ex-dividend Jul 20, 2026
$0.53
Quarterly
Record Jul 20, 2026 · Payment Sep 1, 2026
Ex-dividend Apr 20, 2026
$0.53
Quarterly
Record Apr 20, 2026 · Payment Jun 2, 2026
Ex-dividend Jan 20, 2026
$0.53
Quarterly
Record Jan 20, 2026 · Payment Mar 3, 2026
Ex-dividend Oct 31, 2025
$0.50
Quarterly
Record Oct 31, 2025 · Payment Dec 2, 2025
Ex-dividend Jul 18, 2025
$0.50
Quarterly
Record Jul 18, 2025 · Payment Sep 3, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T58.65B0.05%129.34T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI924.84M0.04%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO858.68M0.05%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO629.24M0.28%226.4B USD0.03%$81.14+0.92%
iShares Core S&P 500 ETFIVV401.47M0.05%892.79B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY370.6M0.05%817.2B USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV278.03M0.11%262.4B USD0.03%$220.59+0.44%
VanEck Morningstar Wide Moat ETFMOAT268.39M2.34%11.5B USD0.46%$108.74+0.32%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
VanEck Morningstar Wide Moat ETFMOATAI-generated and delayed market data for informational and educational purposes only. Not investment advice.